Wednesday - April 15, 2026

Category Archives: Science

Acute On Chronic Liver Failure Clinical Trial Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Acute On Chronic Liver Failure Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 5+ pipeline drugs in the Acute On Chronic Liver Failure pipeline landscape. It covers the Acute On Chronic Liver Failure pipeline drug profiles, … Continue reading →

Pneumococcal Infections Clinical Trial Pipeline Shows Potential with Active Contributions from 15+ Key Companies | DelveInsight

DelveInsight’s, “Pneumococcal infections Pipeline Insights 2026” Report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the Pneumococcal infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Fabry Disease Market Set for Robust Growth by 2034, Driven by Gene Therapy Breakthroughs and Expanding Pipeline from Sangamo, Sanofi, Amicus & Emerging Innovators | DelveInsight

Fabry Disease Market Fabry Disease Companies include Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, … Continue reading →

Bladder Cancer Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

NSCLC Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “NSCLC Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline … Continue reading →

Gastric Cancer Treatment Pipeline Shows Strong Momentum as 200+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Gastric Cancer Pipeline Insight 2026” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

MRSA Infections Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “MRSA Infections Pipeline Insights 2026” Report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in MRSA Infections pipeline landscape. It covers the MRSA Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Sepsis Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Sepsis Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Sepsis pipeline landscape. It covers the Sepsis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sepsis pipeline … Continue reading →

Microbiome Disease Clinical Trial Pipeline Accelerates as 140+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Microbiome Disease Pipeline Insights 2026” Report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the Microbiome Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →